
RISK BENEFIT



Maria Bastaki Methodology and Scientific Support Unit, MESE



**EFSA** 

# RISK BENEFIT ASSESSMENT (RBA) GUIDANCE FOLLOW UP



EC mandate to EFSA for RBA of fish - in dialog process




**Trainings** 



Implementation of guidance



### EC MANDATE FOR RISK-BENEFIT ASSESSMENT OF FISH



#### TERMS OF REFERENCE

• 'In accordance with Art. 29 (1) of Regulation (EC) No 178/2002, the European Commission asks the European Food Safety Authority to provide a risk-benefit assessment of **finfish consumption** by fish species and type (for example but not limited to fatty/lean, predatory/non-predatory, wild-caught/farmed) in relation to the **combined presence** of dioxins (PCDD/Fs) and dioxin-like PCBs, perfluoroalkyl substances (PFAS),polybrominated diphenyl ethers (PBDEs), inorganic arsenic, dimethylarsinic acid(DMA), inorganic mercury and methylmercury in fish.'



## **PURPOSE OF REQUEST**

To produce a risk-benefit assessment that can be used by other competent authorities as input when developing Food-Based Dietary Guidelines.

Aim to give advice on recommended amount of fish consumption depending on level of contamination.





# RBA DESIGN - REFERENCE SCENARIO VS ALTERNATIVES

Reference scenario

Current fish consumption by fish type

Risks by subgroup

••

•••

Benefits by subgroup

•••

•••

Alternative range of scenarios, including 'no fish consumption'

Risks by subgroup

••

•••

Benefits by subgroup


•••

•••






# ITERATIVE PROCESS OF PROBLEM FORMULATION, TOR, RBA





# ANTICIPATED TIMELINE





### **TRAININGS**

- Introductory RBA training in place offered via the EFSA Academy
- More advanced training with experts of all RBA methodologies can be developed following the first implementation of the guidance in the RBA of fish.



# **IMPLEMENTATION OF THE RBA GUIDANCE**

• MS are invited to implement the guidance in house on topics of interest and return feedback on the experience



## **RESULTS OF MS SURVEY - 14 MS RESPONDED (NOVEMBER 2023)**



6 MS conduct RBA in-house: **source of expertise for EFSA**Denmark, France, Germany have their own methods or guidance
Latvia, Norway, Sweden consult EFSA guidance



8 MS interested in co-developing case studies: **source of expertise for EFSA** Cyprus, Denmark, Estonia, France, Germany, Greece, Norway, Poland



10 MS do not conduct RBA in house and/or are interested in EFSA training on the updated guidance: audience for capacity building




#### **ACTIVITIES AND FEEDBACK**

- 8 MS are engaged in national or international collaborative activities (Cyprus, Denmark, France, Germany, Greece, Latvia, Norway, Sweden)
- 5 MS suggested the following aspects be included to the updated guidance to better help them with conducting a Risk Benefit Assessment:
  - √ harmonized methods (DTU, ANSES, KUA, SFA)
  - √ inclusion of alternative metrics to DALYs
  - ✓ quality assessment of publications; weight of evidence
  - ✓ guidance about outcomes marker vs hard endpoints
  - √ "measurable" outputs for better interpretation
  - ✓ examples; case studies
  - ✓ "visual" outputs, such as charts & graphs, in addition to numerical/tabular and decision-trees
  - ✓ short and visual guidance; easily understood and applicable

ongoing work for new guidance on biomarkers of effect M-2025-00074







### RELATED ASSESSMENTS



#### **EFSA** assessments

- 2005 CONTAM wild-farmed fish
- 2012 RA Methylmercury (MeHg)
- 2014 Benefits seafood + RA MeHg
- 2015 RBA MeHg-fish
- 2020 RA PFAS's
- 2024 RA Inorganic As
- 2024 RA Small organic As
- 2024 RA PBDEs
- 2026 RA UPDATE PCDD/Fs + DL-PCBs

#### **External assessments**

- 2022 VKM RA PCDD/Fs and DL-PCBs
- 2022 VKM RBA of fish
- 2024 FAO/WHO RBA of fish
- 2024 ATSDR Mercury Tox Profile
- 2024 ATSDR DRAFT PCDD/F Tox Profile



## **PUBLIC CONSULTATION**







TARGETED MEETING ONLY WITH MS AT THE BEGINNING OF THE PUBLIC CONSULTATION: 3

NO NEED FOR TARGETED
MEETING WITH MS (WRITTEN
COMMENTS SUFFICIENT): 6

ONLY **ONE PUBLIC MEETING** WITH ALL
STAKEHOLDERS: 8



# RBA CAPACITY AMONG MS AND USE OF EFSA GUIDANCE

		CYPRUS	CZECH REPUBL	I DENMARK	ESTONIA	FRANCE	GERMANY	GREECE	LATVIA	MALTA	NORWAY	POLAND	ROMANIA	SPAIN	SWEDEN
PART I –	CONDUCTING RISK BENEFIT ASSESSMENTS														
1	Do you or your office conduct Risk Benefit Assessments of foods?	NO	NO	YES	NO (REM, TAI) N	YES	YES	NO	YES	NO	YES	NO	NO	NO	YES
2	If yes, do you have expertise in-house for this purpose?	N/A	N/A	YES	N/A	YES	YES	N/A	YES	N/A	YES	N/A	N/A	N/A	YES
3	If yes, do you consult the EFSA Guidance for this purpose?	N/A	N/A	NO	YES, if we would	NO	NO	N/A	YES	N/A	YES	N/A	N/A	N/A	YES
3a	If no in Q3, which Guidance do you consult for conducting Risk Bene	€N/A	N/A	While the risk-b	enefit framework	Each Risk Benefi	The BfR guidance	eN/A	N/A	N/A	Also consulting	Hoekstra 2012	N/A	N/A	
3b	If yes in Q3, what do you find challenging in applying the EFSA Guid	N/A	N/A					N/A	Use of guidance	N/A	Hoekstra, 2012 is	s N/G	N/A	N/A	
4	What national or international activities/initiatives on Risk Benefit	Participation in t	NONE	National: develo	No involvment i	We are currently	A workshop on R	The Dept. of Hyg	We were involve	NO ANSWER	International Ris	N/A	Our institution	is We are not awar	A representati
5	What additional aspects do you think should be included in an upd	The updated EFS	N/A	Case studies	Not enough expe	Short and visual	N/A	NO ANSWER	There are no con	NO ANSWER	Quality assessm	€N/A	Not applicable	NO ANSWER	The inclusion of
6	Do you or your office use Risk Benefit Assessments published by Ef	NO	YES	NO	YES	NO	YES	NO	NO		NO	NO	NO	YES	YES
7	If yes, what do you find challenging in (or missing from) the output		NO ANSWER	N/A	NO ANSWER	N/A	N/A (from respo	N/A	N/A			N/A	N/A	We found difficu	The opinions a
8	What type of output (e.g. numerical, tabular, visual, etc) would you		A simplified gra	r NO ANSWER	Visual additiona	Visuals would de	Not applicable fo	visual output	Charts (example	shown in survey	); Raw data/table	sN/A	It would be hel	p The use of decis	i It would be he
PART III.	. CONSULTATION AND FOLLOW UP PHASES														
9	Do you have any preference for the public consultation:						Since the remit of	of the BfR lies wit	thin the area of ris	k assessment, n	ot management, t	his question do	es not fully apply.	(It appears plausil	ble, however, th
	Targeted meeting only with MS at the beginning of the Public Cons		NO	YES		YES			NO			NO	NO		NO
	No need for targeted meeting with MS (written comments sufficient		YES	NO					YES			NO	YES	YES	YES
	Only one public meeting with all stakeholders:		YES	NO	YES			YES	YES			YES	NO	<b>_</b>	YES
	1 1 (0)1 /	Physical						hybrid meeting							
10	Would you be interested in engaging with EFSA in developing case		NO	YES	YES(TAI); NO(REI		The BfR has indic		YES/MAYBE		YES	YES	NO	NO	NO
11	Would you be interested in receiving training on using the updated	YES	NO	NO	YES (REM, LABRIS	YES	YES	YES	YES		YES	YES	YES	We have answer	YES
	Any other comments/suggestions			ed in the Czech Re											

